<DOC>
	<DOCNO>NCT00980473</DOCNO>
	<brief_summary>Glaucoma lead cause irreversible blindness worldwide . With age population , glaucoma morbidity rise , cause increase health care cost economic burden condition visual loss , establish , reverse . In contrast western country , primary angle closure glaucoma ( PACG ) major form glaucoma Asia . In recent population base survey Singapore , prevalence glaucoma 3.2 % Chinese population 40 . Glaucoma lead cause blindness , PACG visually destructive form disease . Laser iridotomy current first line treatment PACG . It act relieve pupil block , turn may reduce intraocular pressure ( IOP ) prevent progression glaucoma . However recent data indicate iridotomy successful control IOP long term , majority case develop clinically significant rise IOP require medical therapy surgery . Argon laser peripheral iridoplasty ( ALPI ) offer new therapeutic option PACG . The procedure consist place contraction burn iris periphery result contraction iris stroma open angle . The propose study 2-centre randomize controlled trial determine whether ALPI effective safe treatment management PACG . 210 patient PACG high IOP ( &gt; 21 mmHg ) follow laser iridotomy randomize receive ALPI medical treatment achieve IOP control . Subjects follow 12 month outcome criterion rate medical treatment surgery group , angle width configuration . This first RCT worldwide address role ALPI PACG . The study find great relevance prevention glaucoma blindness elderly .</brief_summary>
	<brief_title>Argon Laser Peripheral Iridoplasty Primary Angle Closure Glaucoma</brief_title>
	<detailed_description>AIMS AND OBJECTIVES The primary aim study determine whether argon laser peripheral iridoplasty ( ALPI ) effective treatment term intraocular pressure ( IOP ) control case primary angle closure glaucoma ( PACG ) drainage angle remain narrow follow laser iridotomy . Primary outcome measure proportion patient require medical surgical treatment maintain IOP control , number medication require control IOP 12 month follow . The secondary aim determine whether ALPI significantly alter configuration drainage angle compare conventional treatment ( medication ) follow laser iridotomy . Secondary outcome change appearance drainage angle base gonioscopy , ultrasound biomicroscopy anterior segment OCT 1 , 6 12 month follow . The safety ALPI detrimental effect iridoplasty corneal endothelium lens also investigate . STUDY DESIGN The study design project prospective randomize controlled trial . It possible blind either subject observer intervention due use laser intervention group . STUDY POPULATION The study population patient primary angle closure glaucoma attend Singapore National Eye Centre National University Hospital , fulfil inclusion criterion willing take part study . Wash regimen Eligible patient already one two-glaucoma medication require complete washout period randomize . Washout period vary accord previous medication use follow : Prostaglandin analogues 4 week Beta blocker 3 week Adrenergic agonist 2 week Cholinergic agonist 5 day Carbonic Anhydrase Inhibitors 5 day Pre-study washout period check Patients prostaglandin analogue beta blocker prior study require undergo washout period 3 4 week respectively prior study . For group patient , safety check second week . Patients whose IOP &gt; 30 mm Hg washout check stop washout withdrawn study . PLANNED INTERVENTIONS Iridoplasty group For randomise laser iridoplasty , procedure perform follow : A drop brimonidine instill eye treat 15 minute prior procedure . Topical anaesthesia administer Abrahams lens used procedure . Laser burn place 360 degree peripheral iris ( approximately 25 burn total ) . The argon laser set use follow : Initial treatment ( SEAGIG Guidelines ) 28 We request modify laser setting initial treatment laser arm Spot size : 200-500 micron ( change 500 micron ) Power : 150-400 milliwatt ( mw ) increase desired end point achieve ( change 100-300mw ) Duration : 0.2 -0.5 second . Repeat treatment ( one month - three month ) Laser settings 29 Spot size : 200 micron Power : 100-300 milliwatt increase desired end point achieve Duration : 0.5 -0.7 second . The patient give 2 week course topical steroid four time day treat eye . Intraocular pressure check one hour procedure . IOP spike &gt; 25mmHg treat . RE-TREATMENT If follow angle remain narrow gonioscopy UBM/ ASOCT one treatment ALPI give patient try achieve endpoint widening angle . This treatment administer one three month CONTROL GROUP Those patient randomize control group undergo procedure visit . The patient commence topical treatment low IOP . The first line agent lower IOP prostaglandin analogue , stepwise addition Timoptol 0.5 % dorzolamide implement IOP control . If eyes individual patient fulfil inclusion criterion undergo intervention allocate randomization patient . ( see randomization data analysis )</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Persistent narrow angle presence patent laser peripheral iridotomy . A narrow angle define angle width 010ยบ 2 quadrant either eye pigment trabecular meshwork visible 2 quadrant gonioscopic examination Intraocular pressure &gt; 21mmHg topical medication least four week follow laser iridotomy Intra ocular pressure &gt; 21 mm Hg wash regimen describe patient already one medication Iridotomy do least 4 week ago . Informed Consent Age 21 year Age less 21 year Secondary cause angle closure like subluxed lens , uveitis , trauma neovascular glaucoma Presence advance sightthreatening glaucoma define vertical cupdisc ratio &gt; 0.9 Presence significant synechial angle closure &gt; 6 clock hour peripheral anterior synechiae ( define abnormal adhesion iris angle least half clock hour width least anterior trabecular meshwork high indentation gonioscopy ) Cataract deem significant enough require surgery course trial make field test optic disc image technically possible visual acuity le 20/40 due type cataract . Corneal endothelial cell count less 1000 cells/mm2 Corneal abnormalities infection Previous intraocular surgery Use contact lens Chronic use topical systemic steroid Participation another therapeutic drug study within last 30 day Severe health problem preclude followup endstage heart disease , kidney disease , respiratory disease , cancer life expectancy le one year .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Primary Angle Closure Disease</keyword>
</DOC>